13.44
-1.10 (-7.57%)
| Previous Close | 14.54 |
| Open | 14.80 |
| Volume | 38,127,206 |
| Avg. Volume (3M) | 15,380,921 |
| Market Cap | 29,806,559,232 |
| Price / Sales | 20.37 |
| Price / Book | 3.19 |
| 52 Weeks Range | |
| Earnings Date | 18 Aug 2025 - 22 Aug 2025 |
| Profit Margin | -22.88% |
| Operating Margin (TTM) | -5.25% |
| Diluted EPS (TTM) | -0.280 |
| Quarterly Revenue Growth (YOY) | 129.90% |
| Total Debt/Equity (MRQ) | 22.83% |
| Current Ratio (MRQ) | 7.84 |
| Operating Cash Flow (TTM) | -224.98 M |
| Levered Free Cash Flow (TTM) | -1.91 B |
| Return on Assets (TTM) | -2.63% |
| Return on Equity (TTM) | -4.24% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (HK) | Mixed | Mixed |
| Biotechnology (Global) | Bearish | Bearish | |
| Stock | INNOCARE | - | - |
AIStockmoo Score
| Analyst Consensus | 0.0 |
| Insider Activity | NA |
| Price Volatility | -5.0 |
| Technical Moving Averages | 2.5 |
| Technical Oscillators | 2.5 |
| Average | 0.00 |
Similar Stocks
| Stock | Market Cap | DY | P/E (TTM) | P/B |
|---|---|---|---|---|
| INNOCARE | 30 B | - | - | 3.19 |
| BEIGENE | 221 B | - | - | 8.31 |
| HENLIUS | 24 B | - | 26.46 | 8.48 |
| EVEREST MED | 19 B | - | - | 3.78 |
| ASCENTAGE-B | 17 B | - | - | 86.39 |
| INNOVENT BIO | 126 B | - | - | 8.83 |
|
InnoCare Pharma Ltd is a commercial-stage biopharmaceutical company. It discovers, develops, and commercializes drugs for the treatment of cancer and autoimmune diseases. The company's main product pipeline includes orelabrutinib, ibrutinib, zanubrutinib, tafasitamab, ICP-490, ICP-B02, ICP-248, ICP-192, ICP-723, and ICP-189, among others. Its products are mainly used to treat hematological tumors, solid tumors, and autoimmune diseases. The company is also developing products for the treatment of autoimmune diseases caused by abnormal B-cell or T-cell function. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Mid Growth |
| % Held by Insiders | 28.46% |
| % Held by Institutions | 36.20% |
No data within this time range.
No data within this time range.
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |